30PUpdate on the phase II SUMMIT trial: Neratinib + fulvestrant for HER2-mutant, HR-positive, metastatic breast cancer. (13th May 2019) - Smyth, L M; Saura, C; Piha-Paul, S A; Lu, J; Mayer, I A; Brufksy, A M; Spanggaard, I; Arnedos, M; Cutler, R E; Hyman, D M